Long‐term safety and efficacy of sublingual asenapine for the treatment of schizophrenia: A phase III extension study with follow‐up for 52 weeks (P06125)—Secondary publication
Abstract After completion of a 6‐week double‐blind trial of asenapine sublingual tablets (10 or 20 mg/day) versus placebo in Asian patients with acute exacerbation of schizophrenia, including Japanese patients, this open‐label study evaluated the safety and efficacy of a 52‐week treatment with asena...
| Үндсэн зохиолчид: | , , , , |
|---|---|
| Формат: | Өгүүллэг |
| Хэл сонгох: | English |
| Хэвлэсэн: |
Wiley
2023-09-01
|
| Цуврал: | Neuropsychopharmacology Reports |
| Нөхцлүүд: | |
| Онлайн хандалт: | https://doi.org/10.1002/npr2.12342 |